LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...

It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their ...

DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...

The FDA is aware that Dexcom has sent all affected customers an Urgent Medical Device Correction Notification for the Dexcom G7 Continuous Glucose Monitoring (CGM) App (for Android, iOS, and watchOS ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 15-day Dexcom G7 had a MARD of 8%, a small ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...